Arai Takayuki, Sazuka Tomokazu, Sato Hiroaki, Kato Mayuko, Kamada Shuhei, Katsura Sota, Seito Ayako, Miyamoto Shu, Wakai Ken, Takeuchi Nobuyoshi, Imamura Yusuke, Sakamoto Shinichi, Komiya Akira, Ichikawa Tomohiko
Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Int J Clin Oncol. 2022 Sep;27(9):1467-1476. doi: 10.1007/s10147-022-02204-x. Epub 2022 Jun 29.
Late recurrence of renal cell carcinoma (RCC) is observed in some postoperative patients. In addition, some of these patients are lost to long-term postoperative follow-up. We reviewed the treatment results and prognosis of postoperative patients with RCC at Chiba University Hospital, with the aim of clarifying the proportion and background of patients lost to follow-up.
This retrospective study included 1176 RCC patients who underwent radical or/and partial nephrectomy. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and lost follow-up free survival (LFFS) were evaluated and the risk factors for LFFS identified.
The median RFS for stage II and II cases was 188.3 and 104.0 months, respectively. Even in stage I, recurrence was observed in about 20% of patients 20 years after surgery. The Kaplan-Meier curve for LFFS showed a linear descent over time, with 50% of patients lost to follow-up within 25 years. Older age (≥ 62 years), histological type (clear cell RCC), and no recurrence were significant risk factors for lost follow-up.
Long-term follow-up is necessary after RCC surgery because late recurrence cases are not uncommon. We believe that lifelong follow-up with imaging studies is recommended for postoperative RCC patients. Early detection of recurrence in postoperative patients is a very important issue, and it may be worthwhile for improving the prognosis of postoperative patients to focus on patients lost to follow-up who may have been overlooked.
部分肾癌(RCC)术后患者会出现晚期复发。此外,这些患者中有一些在术后长期随访中失访。我们回顾了千叶大学医院肾癌术后患者的治疗结果和预后,旨在明确失访患者的比例及背景。
这项回顾性研究纳入了1176例行根治性或/和部分肾切除术的肾癌患者。评估总生存期(OS)、癌症特异性生存期(CSS)、无复发生存期(RFS)和无失访生存期(LFFS),并确定LFFS的危险因素。
II期和III期病例的中位RFS分别为188.3个月和104.0个月。即使在I期,术后20年仍有约20%的患者出现复发。LFFS的Kaplan-Meier曲线显示随时间呈线性下降,25年内50%的患者失访。年龄较大(≥62岁)、组织学类型(透明细胞肾癌)和无复发是失访的重要危险因素。
肾癌手术后需要长期随访,因为晚期复发病例并不少见。我们认为建议对肾癌术后患者进行终身影像学随访。术后患者复发的早期检测是一个非常重要的问题,关注可能被忽视的失访患者可能有助于改善术后患者的预后。